Effect of Probiotics on gastric inflammatio

Phase 2

Recruiting

• Conditions: Sever atrophic gastritis after Hp eradicaiton; Sever atrophic gastritis, Hp eradicaiton

• Registration Number: JPRN-jRCTs031220708
• Lead Sponsor: Suzuki Takayoshi

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-03-16
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Patient aged 18 years old and older
2. Patients with severe atrophy (O-2 or higher by Kimura/Takemoto classification) or a history of
endoscopic treatment for early differentiated gastric cancer, in which H. pylori was likely involved in
carcinogenesis
3. Patient who had Hp eradication history more than 6 months ago
4. Patient who have been fully informed and have given written consent to participate in this study

Exclusion Criteria

1.Patient who is Hp positive
2.Patient who underwent gastric surgery
3.Patient who is unable to discontinue acid suppressants or probiotics other than LG21 during the study period
4. Patients with a history of food allergy to dairy products
5. A person who is determined to be inappropriate by the principal investigator or subinvestigator

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Degree of improvement in gastric mucosal inflammation findings before and after taking probiotics, obtained at the 2nd and the 4th exam each.

Secondary Outcome Measures

Name	Time	Method
1. Pepsinogen I and Pepsinogen II <br>2. CRP <br>3. pH of gastric juice, LPS activity in the stomach<br>4. gastric flora